• Users Online: 678
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 13  |  Issue : 3  |  Page : 136-141

Can the immature granulocyte count have a role in the diagnosis of coronavirus 2019 disease?


Department of Emergency Medicine, Health Science University Antalya Training and Research Hospital, Antalya, Turkey

Correspondence Address:
Dr. Cihan Bedel
Department of Emergency Medicine, Health Science University Antalya Training and Research Hospital, Kazım Karabekir Street, 07100, Muratpaşa, Antalya
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmbs.ijmbs_43_21

Rights and Permissions

Background: The pathophysiology of COVID-19 disease is not clearly understood; inflammation has been shown to play a major role. The immature granulocytes count (IGC) can be an indicator of inflammation. To the best of our knowledge, there is no data on the usability of IGC for the diagnosis of COVID-19. Objectives: We aim to investigate the usability of the inflammatory marker IGC in the diagnosis of COVID-19. Patients and Methods: COVID-19 patients admitted to a tertiary university hospital were included in this study, and hemogram parameters, white blood cells, hemoglobin, neutrophils, lymphocytes, and IGC were investigated. According to the real-time reverse transcriptional polymerase chain reaction, patients were categorized into two groups as COVID-19 positive and COVID-19 negative. Results: The mean value of IGC was 0.02 (0.02) for the COVID-19-positive group and 0.11 (0.04) for the COVID-19-negative group. Patients with COVID-19 positive were found to have an IGC value that is significantly lower than the other group (P < 0.001). For IGC, it was calculated at a cut-off value of 0.03 (area under the curve: 0.718; sensitivity: 66.7%; specificity: 72.3%; P < 0.001). Conclusions: The results of our study have shown that on-admission IGC level is a novel, cost-effective, and readily available biomarker with a promising predictive marker for COVID-19 patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed642    
    Printed22    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal